Antiangiogenic Agents
Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future
... Ramucirumab is a fully human mAb with low pM affinity to the VEGF-binding domain of VEGFR-2 [113]. Dose-finding studies were undertaken with weekly and every 2 and 3 week single agent administration with very good drug ...
15
Targeted concurrent and sequential delivery of chemotherapeutic and antiangiogenic agents to the brain by using drug-loaded nanofibrous membranes
... chemotherapeutic agents (BCNU, irinotecan, and cisplatin) onto rapidly degrad- ing 50:50 PLGA nanofibers and loaded the antiangiogenic agent (combretastatin) onto 75:25 PLGA ...and antiangiogenic ...
12
Angiogenesis and antiangiogenic agents in cervical cancer
... These data open up the opportunity to study other classes of antiangiogenic agents, including both VEGF-dependent molecules and non-VEGF-dependent molecules. The use of TKI is based on their multitarget ...
12
Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma
... This review summarizes evidence supporting the use of targeted AA in combination with cytotoxic chemo- therapy in sarcomas. We performed an extensive review of the available medical literature using the US National ...
11
“The Antiangiogenic Activity of Commiphora molmol Oleo-Gum-Resin Extracts” by Ghaith A. Jasim, Adeeb A. Al-zubaidy, Shallal M. Hussain, Hayder B. Sahib, Iraq.
... antiangiogenic activity shown by the rat aorta assay, and antioxidant power shown in the DPPH scavenging assay. This may result in a decrease in the free radicals present, which are known to activate the hypoxia ...
8
Antiangiogenic therapy for breast cancer
... Angiogenesis is an important component of cancer growth, invasion and metastasis. Therefore, inhibition of angio- genesis is an attractive strategy for treatment of cancer. We describe existing clinical trials of ...
16
The importance of antiangiogenic effect in multiple myeloma treatment
... new agents in the treatment, multiple myeloma still remains an incurable and debilitating ...Some antiangiogenic agents have already been introduced in multiple myeloma treatment, but there is still ...
7
Cytotoxicity Evaluation and Characterization of Leaf Chloroform Extract of Piper Sarmentosum Possessing Antiangiogenic Activity
... 30]. Antiangiogenic agents are useful in treating diseases involving ...These agents have special significance in cancer treatment because they act on genetically stable endothelial ...
13
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
... contrast, antiangiogenic agents are less effective in less vascularized cancers ...of antiangiogenic agents in micro- versus macrometastatic ...survive antiangiogenic treat- ment in a ...
12
Prolonged survival after sequential multimodal treatment in metastatic renal cell carcinoma: two case reports and a review of the literature
... of antiangiogenic agents that directly inhibit vascular endothelial growth factor (VEGF) (beva- cizumab), others that target VEGF receptors and tyro- sine kinase receptors (sorafenib, sunitinib, pazopanib, ...
6
<p>Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer</p>
... 55 Antiangiogenic agents can sti- mulate the immune system, and immunotherapy can also be ...with antiangiogenic agents are discussed in detail in the following ...
13
Melatonin Reduces Angiogenesis in Serous Papillary Ovarian Carcinoma of Ethanol-Preferring Rats
... Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer. Antiangiogenic agents should be integrated into the standard treatment for patients with ovari[r] ...
36
Serum Vascular Endothelial Growth Factor and Angiopoietin 2 Are Associated with the Severity of Systemic Inflammation Rather than the Presence of Hemoptysis in Patients with Inflammatory Lung Disease
... Antiangiogenic agents have received widespread attention as targets for lung cancer therapy.8,9 Recent studies reported that VEGF elevation correlates significantly with the presence of [r] ...
8
Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics
... which antiangiogenic agents boost the effi- cacy of chemotherapy: (a) a direct effect on neoplastic cell viability and induction of cytotoxicity independently of the vascular effects [22]; (b) impairment of ...
10
Advances in antiangiogenic treatment of small-cell lung cancer
... and Chinese authorities for use as a first-line therapeutic drug in advanced NSCLC. Angiogenesis may be a very early process in vivo which is due to the imbalance between angiogenic and antiangiogenic mediators. ...
7
Vol 27, No 1 (2014)
... In our study, treatment followed a 1+PRN regimen, comprising a bevacizumab and/or ranibizumab injection, as needed, upon the first injection. We found that functional and anatomical benefits were met, alongside with a ...
11
Salvadora persica (Miswak): Antioxidant and Promising Antiangiogenic Insights
... The use of plants to improve dental health and to promote oral hygiene has been practiced for centuries and persists in several communities throughout the world. Salvadora persica (Miswak) has a wide geographic ...
17
Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety
... and antiangiogenic treatments are the basis of treatment in noncurative stages, including interventional and pharmacological ...of antiangiogenic drugs and strategies in intermediate- and advanced-stage ...
11
Treatment of retinal pigment epithelial detachment with antiangiogenic therapy
... two agents provided qualitatively similar benefits, while pegaptanib-treated patients showed somewhat greater improvements in terms of mean visual acuity and retinal thickness despite the overall poorer baseline ...
6
Antiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract
... therapeutic agents targeting ...showed antiangiogenic activity in in vitro and in vivo models, including the inhibition of tube formation and migration of HUVECs and suppression of vascularization in CAM ...
15